Merck & Co Inc
(NYSE:MRK)
$
125.07
-0.92 (-0.73%)
Market Cap: 308.90 Bil
Enterprise Value: 352.37 Bil
PE Ratio: 35.23
PB Ratio: 6.73
GF Score: 72/100 
Merck & Co Inc at Evercore ISI Healthcare Conference Transcript
Dec 02, 2025 / 02:10PM GMT
Release Date Price:
$101.03
(-0.79%)
Chirfi Guindo
Merck & Co Inc - Senior Vice President, Chief Marketing Officer - Human Health
So thank you. We're ready to go.
Questions & Answers
Umer Raffat
Evercore Inc - Equity Analyst
All right, fantastic. So we'll jump right in. I want to do R&D and commercial. Do we have a preference where we should start?
Chirfi Guindo
Merck & Co Inc - Senior Vice President, Chief Marketing Officer - Human Health
Up to you.
Eliav Barr
Merck & Co Inc - Senior Vice President, Head of Global Clinical Development and Chief Medical Officer
It's up to you.
Umer Raffat
Evercore Inc - Equity Analyst
Okay, we'll start maybe a little bit on the R&D side, and we'll come back to commercial, then probably go back into R&D again.
Maybe in no particular order, let me start with the CADENCE trial, clear success, but it looks like for -- there were these questions around whether it was enough to warrant
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers